Throughout her career, One2Treat’s Émilie Barré has focused on developing both the analytical and leadership aspects ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback